Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ayahuasca alkaloids
- Development stage
- Unknown
- Lead developer
- Biochem Industries
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Ayahuasca alkaloids is a botanical extract research compound developed by Biochem Industries Pty Ltd, consisting of the primary psychoactive constituents of the traditional ayahuasca brew. The formulation includes N,N-dimethyltryptamine (DMT) and harmala alkaloids such as harmine, harmaline, and tetrahydroharmine. DMT serves as a potent agonist of the serotonin 5-HT2A receptor, while the harmala alkaloids act as reversible inhibitors of monoamine oxidase A (MAO-A), preventing the peripheral degradation of DMT and allowing it to reach the central nervous system when administered orally. It is currently being evaluated in pilot clinical trials as a microdose formulation for its potential to modulate neurotransmitter levels, inflammatory markers, and mood self-efficacy, with a focus on applications in cognitive impairment.
- Other names
- ayahuasca extractDMT + harmala alkaloids
02
Targets
HTR2A (Serotonin receptor 5-HT2A)SERT (Sodium-dependent serotonin transporter)MAOA (Monoamine oxidase A)
Beyond the preview
Go deeper on ayahuasca alkaloids.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ayahuasca alkaloids.